Crossref
Tepotinib (Tepmetko) for NSCLC
The Medical Letter on Drugs and Therapeutics · 2024
DOI: 10.58347/tml.2024.1701f ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Rosacea.
Abstract (Originalsprache)
The FDA has granted regular approval to the oral kinase inhibitor tepotinib (Tepmetko – EMD Serono) for treatment of adults with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
RosaceaHumansDermatologic AgentsAdministration, CutaneousAdministration, Topical
Stichwörter der Autor:innen
Tepmetkoadverse effectsdosagedrug interactionsefficacylactationlung cancerpregnancysafetytepotinib
Substanzen
Dermatologic Agents
Zitieren
APA
(2024). Tepotinib (Tepmetko) for NSCLC. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1701f
Vancouver
Tepotinib (Tepmetko) for NSCLC. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1701f
BibTeX
@article{euvimed2024,
title = {Tepotinib (Tepmetko) for NSCLC},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2024},
doi = {10.58347/tml.2024.1701f}
}
EUVIMED